A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The Primary objective is to assess the non-inferiority of the experimental arm (arm B)
compared to the control arm (arm A) in terms of Major Molecular Response (MMolR) after the
4th cycle (MRD4) in patients aged 18-59 years old with de novo Philadelphia positive (Ph+)
acute lymphoblastic leukemia (ALL)